

Atty's Docket: 101195-63

IN THE CLAIMS

Amend the claims as follows:

1. (Currently amended) An immunoadsorber for blood treatment use in sepsis therapy, the immunoadsorber comprising a carrier of organic or synthetic polymers to which are immobilized antibodies that ~~bind~~ are specific to C3a and/or C5a and to lipopolysaccharides (LPS) and wherein,
 - a) the antibodies to C3a are specific for at least one peptide selected from the group consisting of SEQ ID NO: 1, 2, and 3; and
 - b) the antibodies to C5a are specific for at least one peptide selected from the group consisting of SEQ ID NO: 4, and 5.
2. (Previously presented) The immunoadsorber according to Claim 1, wherein the antibodies are polyclonal antibodies.
3. (Previously presented) The immunoadsorber according to Claim 2, wherein the antibodies are avian antibodies of type IgY.
4. (Currently amended) The immunoadsorber of Claim 4~~5~~, wherein the immobilized antibodies comprising the immunoadsorber are varied as a function of the actual content of sepsis mediators in the blood.
5. (Currently amended) The immunoadsorber according to Claim 1, further comprising at least one immobilized antibody ~~directed against~~ specific for at least one sepsis mediator selected from the group consisting of TNF, 1L1, 1L6, IL8 and/or IL10.
6. (Canceled).
7. (Previously presented) The immunoadsorber according to Claim 5, wherein the immobilized antibodies are specific for at least one of the following peptide sequences of interleukins 1 α and 1 β

IL1 α : NH₂-NCYSENEEDSSSID-COOH SEQ ID NO. 6
NH₂-GAYKSSKDDAKIT-COOH SEQ ID NO. 7

Atty's Docket: 101195-63

NH2-WETHGTKNYFTS-COOH SEQ ID NO. 8

IL β : NH2-RISDHHYSKGFRQA-COOH SEQ ID NO. 9

NH2-VQGEESNDKIPVA-COOH SEQ ID NO. 10

NH2-ESVDPKNYPKKKMEKRF-COOH SEQ ID NO. 11

8. (Previously presented) The immunoadsorber according to Claim 5, wherein the immobilized antibodies are specific for at least one of the following peptide sequences of interleukin 6:

IL6: NH2-APHRQPLTSSERIDKQI- COOH SEQ ID NO. 12

NH2-QNRFESSEEQARA- COOH SEQ ID NO. 13

NH2-AITTPDPTTNAS- COOH SEQ ID NO. 14.

9. (Previously presented) The immunoadsorber according to Claim 5, wherein the immobilized antibodies are specific for at least one of the following peptide sequences of interleukin 10

IL10: NH2-SPGQGTQSENSCT-COOH SEQ ID NO. 15

NH2-QMKDQLDNLKES-CCOH SEQ ID NO. 16

NH2-MPQAENQDPDIKA-COOH SEQ ID NO. 17

NH2-LPCENKSKAVEQ-COOH SEQ ID NO. 18.

10. (Previously presented) The immunoadsorber according to Claim 5, wherein the immobilized antibodies are specific for at least one of the following peptide sequences of TNF α

TNF α : NH2-VRSSSRTPSDKPVA-COOH SEQ ID NO. 19

NH2-KSPCQRETPEGAEAKPW-COOH SEQ ID NO. 20.

11. (Previously presented) The immunoadsorber according to Claim 1, wherein the organic or synthetic polymers further comprise membranes or particles of one or more of the group consisting of polystyrenes, carbohydrates cellulose, agarose derivatives, and acrylates.

Atty's Docket: 101195-63

12. (Previously presented) The immunoadsorber according to Claim 1, wherein the immobilized antibodies are covalently bound to the carrier.

13. (Previously presented) The immunoadsorber according to Claim 1, wherein the immobilized antibodies are attached to the carrier via spacers or linkers.

14. (Previously presented) A method for the production of immunoadsorber according to Claim 1, wherein antibodies specific for C3a and/or C5a and LPS and, optionally, against further sepsis mediators are covalently or adsorptively coupled to the carrier.

15. (Previously presented) A method according to Claim 14, wherein the antibodies are produced by immunisation of mammals or birds with the corresponding antigens.

16. – 17. (Canceled).

18. (Currently amended) A method of treating blood plasma or serum using the immunoadsorber of claim 1, the method comprising the steps of,

providing an amount of blood plasma or serum in need of sepsis therapy; and
contacting the blood with the immunoadsorber of claim 1;

and recovering the ~~treated~~ contacted blood plasma or serum from the immunoadsorber.

19. (Previously presented) The method of claim 18, wherein the blood plasma or serum has not been subjected to hemofiltration prior to contacting the immunoadsorber.

20. to 27. (Canceled)

28. (Previously presented) The method of claim 15 wherein the antibodies are raised by immunizing one or more animals selected from the group consisting of mice, rats, rabbits or chickens.